Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions
Year: 2025
Type: article
Abstract: Metabolic-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) are interrelated metabolic disorders with significant global health impacts. MASLD, the hepatic manifestation of metabolic dysfunction, is driven by insulin resistance, ectopic lipid accumulation, and systematic inflammation. T2DM exacerbates the progression of MASLD, increasing the risk of advanced fibrosis, cardiovascular complications, and hepatocellular carcinoma (HCC). This bidirectional relationship highlights the need for integrated management strategies. The pathology of these conditions involves disrupted lipid and glucose metabolism, leading to a cycle of metabolic dysfunction which worsens both hepatic and systemic outcomes. Non-invasive diagnostic tools have improved early detection but lack precision in staging liver disease, emphasizing the need for more accurate biomarkers. Routine screening for MASLD in diabetic populations is critical for early intervention. Management focuses on weight reduction through lifestyle changes, although long-term adherence remains a challenge. Pharmacological advancements, including glucagon-like peptide-1 receptor agonists (GLP-1Ras) and sodium–glucose cotransporter-2 (SGLT2) inhibitors, show promise in reducing liver fat, improving glycemic control, and slowing fibrosis progression. However, these therapies are less effective in advanced stages of fibrosis and cirrhosis, underscoring the need for novel treatment options. In conclusion, the intertwined nature of MASLD and T2DM necessitates a multidisciplinary approach integrating early diagnosis, lifestyle interventions, and targeted therapies. Future research should prioritize refining diagnostic accuracy and developing innovative treatments for delivering personalized care strategies to mitigate the growing burden of these conditions. These efforts are crucial for improving outcomes in this vulnerable population.
Source: Diabetology
Institution: University of West Attica
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,448
OpenAlex ID: W4408828004